Physician profile
Joel David
NPI 1942560222
$4,135.66
in general payments reported to CMS, 2019-2025
47 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $198 · 2021: $155 · 2022: $1,095 · 2023: $877 · 2024: $678 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $508.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $397.58 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $302.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $282.07 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $223.01 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $219.48 | 2020-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $190.33 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Abbott Laboratories | $162.69 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $156.50 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $137.57 | 2022-2025 | |
| Dynavax Technologies Corporation | $124.20 | 2022-2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.04 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Straumann USA LLC | $120.83 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $108.02 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $95.20 | 2023-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.